Jasper Therapeutics, Inc. (JSPR) NASDAQ
0.53
-0.2948(-35.56%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.53
-0.2948(-35.56%)
Currency In USD
Address
2200 Bridge Pkwy
Redwood City, CA 94065
United States of America (the)
Phone
650 549 1400
Sector
Healthcare
Industry
Biotechnology
Employees
64
First IPO Date
January 10, 2020
| Name | Title | Pay | Year Born |
| Jeetinder Singh Mahal | President, COO, CEO & Director | 610,050 | 1973 |
| Judith Anne Shizuru | Co-Founder, Member of Scientific Advisory Board & Director | 46,300 | 1957 |
| Thomas G. Wiggans | Executive Chairman | 70,000 | 1952 |
| Herbert C. Cross | Chief Financial Officer & Corporate Secretary | 603,925 | 1972 |
| Luca Di Noto | Senior Vice President of Technical Operations | 0 | N/A |
| Matthew Ford | Senior Vice President of Human Resources | 0 | N/A |
| Patricia Carlos | Senior Vice President of Regulatory Affairs & Quality | 0 | N/A |
| Daniel C. Adelman | Acting Chief Medical Officer, Member of Scientific Advisory Board & Senior Clinical Advisor | 0 | 1957 |
| Alex Gray | Head of Investor Relations | 0 | N/A |
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.